Clinical Trials Arena July 11, 2024
According to a recent survey by biopharma solutions provider Cytiva, resilience remains a critical priority for industry leaders. But as companies continue to face economic and supply chain headwinds, embedding resilience into the business of biopharma remains a daunting challenge.
Biomanufacturing has had an interesting couple of years. Unprecedented spikes in demand from the global COVID-19 pandemic have been followed by a period of financial uncertainty, putting the industry under enormous strain.
How are firms responding? Cytiva, a provider of life sciences tools and technology, recently surveyed biopharma leaders to find out where the industry stands on five key pillars: supply chain resilience, talent pool, R&D collaboration, manufacturing agility and government policy and regulation.
Data gathered from 1250...
Today's Sponsors
Today's Sponsor